The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer.
 
Mehrdad Rakaee
No Relationships to Disclose
 
Masoud Tafavvoghi
No Relationships to Disclose
 
Elio Adib
Employment - Amgen (I)
 
Biagio Ricciuti
Consulting or Advisory Role - Regeneron
 
Joao Victor Machado Alessi
No Relationships to Disclose
 
Alessio Cortellini
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IQvia; MSD Oncology; OncoC4
Speakers' Bureau - AstraZeneca; Eisai
 
Claudia A.M. Fulgenzi
No Relationships to Disclose
 
Kajsa Møllersen
No Relationships to Disclose
 
Lars Ailo Bongo
No Relationships to Disclose
 
Sayed MS Hashemi
Consulting or Advisory Role - Janssen; Lilly; Merck
Research Funding - AstraZeneca/MedImmune (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); takeda (Inst)
 
Ilias Houda
No Relationships to Disclose
 
Lill-Tove Rasmussen Busund
No Relationships to Disclose
 
Tom Donnem
No Relationships to Disclose
 
Idris Bahce
No Relationships to Disclose
 
David J. James Pinato
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Lift Biosciences; Mursla Bio; Roche/Genentech; Starpharma
Consulting or Advisory Role - AstraZeneca; Da Volterra; EISAI; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
Other Relationship - Wiley
 
Lynette M. Sholl
Stock and Other Ownership Interests - Moderna Therapeutics (I)
Consulting or Advisory Role - AstraZeneca; Genentech (Inst); Lilly (Inst)
Research Funding - Bristol Myers Squibb (Inst); Roche/Genentech (Inst)
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gilead Sciences; Gritstone Bio; Hengrui Therapeutics; Instil Bio; Janssen Oncology; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
David J. Kwiatkowski
Consulting or Advisory Role - AADI; Genentech/Roche
Research Funding - AADi; Genentech/Roche; Revolution Medicines